CompletedNot Applicable

Effects of a Dietary Supplement on Collagen Production and Evaluation of Its Regenerative and Anti-Ageing Propertiess

Greece92 participantsStarted 2025-10-01

Plain-language summary

This study evaluates the effects of a dietary supplement containing natural bioactive compounds on biological processes associated with skin ageing and extracellular matrix integrity. Ageing is characterized by a progressive decline in the function of dermal fibroblasts, the primary cells responsible for collagen production and maintenance of skin structure. Over time, these cells exhibit reduced proliferative capacity, decreased collagen synthesis, and increased accumulation of oxidative and glycative damage, leading to deterioration of skin elasticity and overall tissue homeostasis. The study integrates in vitro and clinical approaches to investigate the potential benefits of the formulation. In the clinical component, healthy adult participants received either the nutraceutical formulation or a matched placebo daily for a period of six weeks. Blood samples were collected at baseline and at the end of the intervention to assess changes in systemic biomarkers associated with collagen metabolism, oxidative stress, and glycation. Specifically, the study measured circulating levels of Pro-Collagen I Alpha as an indicator of collagen biosynthesis, protein carbonyls as markers of oxidative protein damage, and Advanced Glycation End Products as markers of glycation-related molecular damage. These biomarkers collectively reflect key biological mechanisms underlying skin ageing and broader ageing processes. The objective of the study is to determine whether supplementation with the formulation can support extracellular matrix homeostasis, enhance collagen production, and reduce molecular damage associated with oxidative stress and glycation, thereby contributing to healthy ageing.

Who can participate

Age range29 Years – 82 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Adults aged 29 to 82 years Individuals with Fitzpatrick skin types I-VI Presence of mild to moderate fine lines and wrinkles Presence of mild to moderate photoaging consistent with chronological ageing Generally healthy individuals without known medical conditions that, in the opinion of the investigator, could interfere with study participation Ability to understand the study procedures and provide written informed consent Exclusion Criteria: 1\. Body mass index (BMI) greater than 28 kg/m² Current diagnosis of cancer and/or undergoing chemotherapy or radiotherapy Use of dietary supplements during the study period Ongoing long-term treatment for autoimmune or chronic diseases Pregnancy, breastfeeding, or intention to become pregnant during the study period Severe photoaging beyond mild to moderate classification History of cosmetic procedures or dermatological conditions that, in the opinion of the investigator, could interfere with accurate skin assessment, including but not limited to rosacea, acne, or excessively oily or dry skin Known hypersensitivity or allergic reaction to any component of the study product

What they're measuring

Change in plasma Pro-Collagen I Alpha levels

Timeframe: Baseline (Day 0) and Week 6

Change in plasma protein carbonyl levels

Timeframe: Baseline (Day 0) and Week 6

Change in plasma Advanced Glycation End Products (AGEs) levels

Timeframe: Baseline (Day 0) and Week 6

Trial details

NCT IDNCT07521423

SponsorMarianna Kapetanou

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-01

View on ClinicalTrials.gov More Healthy Ageing trials

Plain-language summary

Who can participate

Age range29 Years – 82 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.